Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul;162(1):288-292.
doi: 10.1016/j.jtcvs.2021.02.008. Epub 2021 Feb 9.

Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons

David R Jones  1 , Yi-Long Wu  2 , Masahiro Tsuboi  3 , Roy S Herbst  4
Affiliations
Editorial

Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons

David R Jones et al. J Thorac Cardiovasc Surg. 2021 Jul.

Abstract

Estimates of disease-free survival in patients with pathologic stage IB to IIIA disease.

Keywords: ADAURA; EGFR; lung adenocarcinoma; osimertinib.

PubMed Disclaimer

Comment in

References

    1. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana H, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018; 378: 113–25. - PubMed
    1. Brandt W, Bouadallah I, Tan KS, Park BJ, Adusumilli PS, Molena D, et al. Predictors of distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. J Thorac Cardiovasc Surg. 2018;155:1212–24. - PMC - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–9. - PubMed
    1. Kelly K, Altorki NK, Eberhardt WEE, O’Brien MER, Spigel DR, Crinò L, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33:4007–14. - PubMed
    1. Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;11:863–873. - PubMed

Publication types

MeSH terms